This is a free preview for the upcoming Harpoon Therapeutics IPO.
Company: Harpoon Therapeutics, Inc.
Symbol: HARP
Description: They are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
Shares: 5.4 million
Price Range: $13.00-$15.00
Trade Date: 2/8
Underwriter(s): Citigroup, SVB Leerink
Co-Manager(s): Canaccord Genuity, Wedbush PacGrow
Terms Added: 1-29-19
Business : T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using their proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, they are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Since commencing operations in 2015, they have created four TriTAC product candidates, and they expect to have four TriTACs in clinical development by the end of 2020. Their lead TriTAC product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC, and they recently announced preliminary data that supports the proposed mechanism of action of HPN424. Their second TriTAC product candidate, HPN536, is expected to enter clinical development in the first half of 2019 for the treatment of ovarian cancer and other mesothelin, or MSLN, expressing solid tumors.
The following table summarizes key information about their product candidates to date, all of which were developed using their TriTAC platform.
IPO Boutiuqe Color, Commentary & Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish